赫赛汀联合多西他赛治疗转移性乳腺癌的效果评价

Evaluation of the effect of Herceptin combined with docetaxel in the treatment of metastatic breast cancer

目的探究赫赛汀联合多西他赛治疗转移性乳腺癌的临床效果。方法80例转移性乳腺癌患者,依据入院先后顺序分为对照组与观察组,各40例。对照组采用赫赛汀治疗,观察组采用赫赛汀联合多西他赛治疗。对比两组治疗效果、不良反应发生情况及治疗前后相关临床指标[C反应蛋白(CRP)、白细胞介素6(IL-6)、体力状况评定量表(KPS)评分]。结果观察组治疗总有效率为90.00%,高于对照组的70.00%,差异有统计学意义(P<0.05)。观察组不良反应发生率为12.50%,低于对照组的40.00%,差异有统计学意义(P<0.05)。治疗后,观察组CRP、IL-6水平及KPS评分分别为(4.17±0.90)mg/L、(1.72±0.22)μg/L、(80.50±6.50)分,均优于对照组的(6.15±1.10)mg/L、(1.50±0.20)μg/L、(71.50±5.50)分,差异均有统计学意义(P<0.05)。结论赫赛汀联合多西他赛治疗转移性乳腺癌效果理想、安全性高,有效调控炎性因子,提高患者的生活质量。

Objective To investigate the clinical effect of Herceptin combined with docetaxel in the treatment of metastatic breast cancer.Methods A total of 80 patients with metastatic breast cancer were divided into control group and observation group according to the order of admission,with 40 cases in each group.The control group was treated with Herceptin,and the observation group was treated with Herceptin combined with docetaxel.Both groups were compared in terms of therapeutic effects,occurrence of adverse reactions and related clinical indicators[C-reactive protein(CRP),interleukin-6(IL-6),karnofsky performance status(KPS)score]before and after treatment.Results The total effective rate 90.00%of the observation group was higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 12.50%in the observation group was lower than 40.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CRP,IL-6 and KPS score in the observation group were(4.17±0.90)mg/L,(1.72±0.22)μg/L,and(80.50±6.50)points,which were all better than(6.15±1.10)mg/L,(1.50±0.20)μg/L,and(71.50±5.50)points in the control group,and the differences were statistically significant(P<0.05).Conclusion Herceptin combined with docetaxel has an ideal effect and high safety in the treatment of metastatic breast cancer,and can effectively regulate inflammatory factors and improve the quality of life of patients.